Moody SC, Fietz D, Nathaniel B, Frydenberg M, Tran B, Schuppe H, Loveland KL. Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours. Andrology. 2026;14(1):10.1111/andr.70100
Chen DC, Buteau JP, Papa N, Akhurst T, Alipour R, Bollampally N, Cardin A, Eifer M, Casanueva Eliceiry S, Jackson P, Jewell K, Kashyap R, Kong G, Kostos L, Ravi Kumar A, McIntosh L, Medhurst E, Saghebi J, Sandhu S, Murphy DG, Tran B, Azad AA, Hofman MS. Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.Journal of Nuclear Medicine. 2025;66(12):10.2967/jnumed.125.270804
Bainomugisa CK, Dasgupta P, Cameron JK, Tran B, Cramb SM, Baade PD. Spatial patterns of testicular cancer diagnosis in Australia, 2010-2019. Spatial and Spatio-temporal Epidemiology. 2025;55:10.1016/j.sste.2025.100745
Shahnam A, Hitchen N, Manoharan S, John T, Mileshkin L, Solomon B, Sandhu S, Luen SJ, Desai J, Tran B. Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies. Journal of Geriatric Oncology. 2025;16(8):10.1016/j.jgo.2025.102721
Hiong A, Lynam J, Weickhardt A, Wong S, Sengupta S, Manohar P, Wong L, Dundee P, Lawrentschuk N, Zhang AY, Anton A, Raghunath A, Gibbs P, Tran B. Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia. BJUI Compass. 2025;6(9):10.1002/bco2.70083
Sandhu SK, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, Chan J, Banks PD, Wallace R, Hamid A, Inderjeeth AJ, Alipour R, Kong G, Kumar ASR, Tran B, Tolmeijer SH, Buteau JP, Williams S, Hicks RJ, Hofman MS. 2391P LuPARP: Phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 2025;36:10.1016/j.annonc.2025.08.3007
Ottaviano M, Pecoraro G, Paffenholz P, Mallardo D, Terbuch A, Secondino S, Basso U, Barrera RM, Tran B, De Giorgi U, Mego M, Cathomas R, Bastos DA, Rescigno P, Ascierto PA, Heidenreich A, Gillessen S, Vogl U. 1050P Characteristics, treatments and outcomes in patients with germ cell tumors (GCTs) relapsing ≥2 years after chemotherapy or initiation of active surveillance: Findings from the RELAGERM retrospective cohort study. Annals of Oncology. 2025;36:10.1016/j.annonc.2025.08.1690
Kostos LK, Buteau JP, Xie J, Cardin A, Jackson P, Chin K, Garcia Q, Haskali M, Emmerson B, MacFarlane L, Kong G, Parker BS, Chan J, Hamilton AJ, Wang Y, Au L, Tran B, Murphy D, Azad AA, Hofman MS. 2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial. Annals of Oncology. 2025;36:10.1016/j.annonc.2025.08.3002
Aziz NA, Ng K, Alifrangis C, Tran B, Conduit C, Liow E, Ackerman C, Georgescu R, Jamal T, Relton C, Mayer E, Nicol D, Cazzaniga W, Huddart R, Reid A, Shamash J, Rajan P. Therapy de‐escalation for testicular cancer (THERATEST): A multi‐centre observational cohort feasibility study of de‐escalation therapies for good prognosis stage II germ cell tumours. BJUI Compass. 2025;6(8):10.1002/bco2.70057
Furic L, Ferreira R, Hannan K, Kusnadi E, Panov K, George A, Huglo A, Lawrence M, Tran B, Desai J, Drygin D, Haddach M, Hein N, Hannan RD. 77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial. ESMO Open. 2025;10:10.1016/j.esmoop.2025.105427
